A large travel-associated outbreak of iatrogenic botulism in four European countries following intragastric botulinum neurotoxin injections for weight reduction, Türkiye, February to March 2023

In March 2023, 34 associated cases of iatrogenic botulism were detected in Germany (30 cases), Switzerland (two cases), Austria (one case), and France (one case). An alert was rapidly disseminated via European Union networks and communication platforms (Food- and Waterborne Diseases and Zoonoses Network, EpiPulse, Early Warning and Response System) and the International Health Regulation mechanism; the outbreak was investigated in a European collaboration. We traced sources of the botulism outbreak to treatment of weight loss in Türkiye, involving intragastric injections of botulinum neurotoxin. Cases were traced using a list of patients who had received this treatment. Laboratory investigations of the first 12 German cases confirmed nine cases. The application of innovative and highly sensitive endopeptidase assays was necessary to detect minute traces of botulinum neurotoxin in patient sera. The botulism notification requirement for physicians was essential to detect this outbreak in Germany. The surveillance case definition of botulism should be revisited and inclusion of cases of iatrogenic botulism should be considered as these cases might lack standard laboratory confirmation yet warrant public health action. Any potential risks associated with the use of botulinum neurotoxins in medical procedures need to be carefully balanced with the expected benefits of the procedure.

[1]  F. Burckhardt,et al.  First cross-border outbreak of foodborne botulism in the European Union associated with the consumption of commercial dried roach (Rutilus rutilus) , 2023, Frontiers in Public Health.

[2]  L. Chou,et al.  Efficacy and Optimal Dose of Botulinum Toxin A in Post-Stroke Lower Extremity Spasticity: A Systematic Review and Meta-Analysis , 2021, Toxins.

[3]  W. Luo,et al.  Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective , 2021, Frontiers in Psychiatry.

[4]  I. Malaty,et al.  An Update on Botulinum Toxin in Neurology. , 2021, Neurologic clinics.

[5]  D. Dressler.  Clinical Pharmacology of Botulinum Toxin Drugs. , 2020, Handbook of experimental pharmacology.

[6]  Chih-Kun Huang,et al.  Intragastric Botulinum Toxin A Injection Is an Effective Obesity Therapy for Patients with BMI > 40 kg/m2: a Systematic Review and Meta-analysis , 2020, Obesity Surgery.

[7]  T. Alster,et al.  Alternative Clinical Indications of Botulinum Toxin , 2020, American Journal of Clinical Dermatology.

[8]  Florian Thiery,et al.  Linked COVID-19 Data: Johns Hopkins University (JHU) and European Centre for Disease Prevention and Control (ECDC) , 2020 .

[9]  C. Montecucco,et al.  Botulinum Neurotoxins: Mechanism of Action. , 2020, Handbook of experimental pharmacology.

[10]  D. Stern,et al.  Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology , 2019, Scientific Reports.

[11]  Suzanne R. Kalb,et al.  Notes from the Field: Intestinal Colonization and Possible Iatrogenic Botulism in Mouse Bioassay–Negative Serum Specimens — Los Angeles County, California, November 2017 , 2018, MMWR. Morbidity and mortality weekly report.

[12]  P. Keim,et al.  Botulinum Neurotoxin-Producing Bacteria. Isn’t It Time that We Called a Species a Species? , 2018, mBio.

[13]  Martin Skiba,et al.  Replacing the mouse bioassay for diagnostics and potency testing of botulinum neurotoxins – progress and challenges , 2018 .

[14]  B. Mégarbane,et al.  Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation – A Descriptive Series of Patient Features and Outcome , 2018, Basic & clinical pharmacology & toxicology.

[15]  M. Santo,et al.  Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis , 2017, Obesity Surgery.

[16]  Suzanne R. Kalb,et al.  Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry , 2017, Analytical and Bioanalytical Chemistry.

[17]  Suzanne R. Kalb,et al.  Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature , 2017, Toxins.

[18]  Werner Luginbühl,et al.  Qualitative and Quantitative Detection of Botulinum Neurotoxins from Complex Matrices: Results of the First International Proficiency Test , 2015, Toxins.

[19]  Suzanne R. Kalb,et al.  Recommended Mass Spectrometry-Based Strategies to Identify Botulinum Neurotoxin-Containing Samples , 2015, Toxins.

[20]  B. Mohammadi,et al.  Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport® , 2015, Journal of Neural Transmission.

[21]  J. Frevert.  Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products , 2015, Drugs in R&D.

[22]  Curtis N. James,et al.  Biologics: Targets and Therapy Dovepress Video Abstract Botulinum Toxin Type a Products Are Not Interchangeable: a Review of the Evidence , 2022 .

[23]  S. Kirchner,et al.  Pentaplexed Quantitative Real-Time PCR Assay for the Simultaneous Detection and Quantification of Botulinum Neurotoxin-Producing Clostridia in Food and Clinical Samples , 2010, Applied and Environmental Microbiology.

[24]  P. Skipper,et al.  An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin , 2009, Journal of applied microbiology.

[25]  M. Mewies,et al.  Serious issues relating to the clinical use of unlicensed botulinum toxin products. , 2009, Journal of the American Academy of Dermatology.

[26]  T. Hunt,et al.  Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. , 2008, Journal of the American Academy of Dermatology.

[27]  M. Camilleri,et al.  Endoscopic Ultrasound-Guided Gastric Botulinum Toxin Injections in Obese Subjects: A Pilot Study , 2008, Obesity surgery.

[28]  Suzanne R. Kalb,et al.  The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. , 2006, Analytical biochemistry.

[29]  S. Panunzi,et al.  Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study , 2006, Alimentary pharmacology & therapeutics.

[30]  P. Savassi-Rocha,et al.  Botulinum A Toxin Injected into the Gastric Wall for the Treatment of Class III Obesity: A Pilot Study , 2006, Obesity surgery.

[31]  M. Petroni,et al.  Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study , 2005, Journal of Gastroenterology.

[32]  Suzanne R. Kalb,et al.  From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. , 2005, Analytical chemistry.

[33]  C. Montecucco,et al.  Botulinal neurotoxins: revival of an old killer. , 2005, Current opinion in pharmacology.

[34]  M. Manns,et al.  Antral injections of botulinum a toxin for the treatment of obesity. , 2003, Annals of internal medicine.

[35]  Reinhard Dengler,et al.  Botulinum A Toxin: Dysport Improvement of Biological Availability , 2001, Experimental Neurology.

[36]  C. Shone,et al.  Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities , 1996, Journal of clinical microbiology.

[37]  A. Pickett.  Counterfeit Botulinum Medical Products and Risk of Bioterrorism , 2014 .

[38]  Paolo Manganotti,et al.  European consensus table on the use of botulinum toxin type A in adult spasticity. , 2009, Journal of rehabilitation medicine.

[39]  Eric A. Johnson,et al.  Chapter 11 Botulism , 2008 .